|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||29.98 - 30.27|
|52 Week Range||26.30 - 32.42|
|PE Ratio (TTM)||23.79|
|Forward Dividend & Yield||1.08 (3.84%)|
|1y Target Est||33.33|
Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.
OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair® (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to them through FDA approval as soon as possible.
Diabetes treatment has evolved since Mary Fortune was diagnosed in 1967 and hospitalized because there was no reliable way monitor her blood sugar. Fortune and other diabetics are benefiting from an explosion in technology and innovation, from under-the-skin sensors that eliminate the need for painful finger pricks, to smartphone alerts when glucose levels rise too high. For glucose monitors alone, the number of published patent applications has grown steadily for a decade and has accelerated significantly since 2015, according to an analysis by the research firm Patinformatics.
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. At a market cap of $236.2 million, experienced biotech investors will expect higher than normal volatility. On Monday, Protagonist announced that it secured $22 million in equity financing through the sale of 2.75 million shares.
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
Bristol-Myers Squibb (BMY) has key licensing arrangements with Biogen (BIIB) and Roche Holding (RHHBY). It out-licensed the exclusive rights to develop and commercialize BMS-986168 to Biogen in the second quarter of 2017. This compound is in development for the treatment of progressive supranuclear palsy.
During the second-quarter earnings call, Horizon Pharma (HZNP) will focus on the performance of business units along with that of Actimmune and Krystexxa and update on teprotumumab's development.
Regeneron Pharmaceuticals on Thursday reported adjusted income of $5.45 per share on $1.61 billion in sales for the second quarter.
Recent decisions by some of the major US branded drug manufacturers not to institute price increases at mid-year, or for the remainder of 2018, reflect the heightened prospect of increasing government regulation on drug pricing, Moody's Investors Service says in a new report. "The decision to forego customary price increases will raise pricing pressure on US branded drug makers," said Michael Levesque, a Moody's Senior Vice President. For the time being, there remains a large difference between gross and net price increases, since drug companies pay rebates to pharmacy benefit managers and rebates are rising, Levesque says.
How Is Merck Positioned in H2 2018? In Q2 2018, Merck’s (MRK) Keytruda generated revenues of $1.67 billion compared to $881.0 million in Q2 2017, reflecting ~89% YoY growth. In Q2 2018, in the US and international markets, Keytruda generated revenues of $959.0 million and $707.0 million, respectively, compared to $556.0 million and $325.0 million in Q2 2017, reflecting ~73% and ~118% YoY growth.
Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.
OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced that Roche`s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.00 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 30 July 2018 and was not extended.
- Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care - Digital tools and data-based analytics facilitate operational and ...
OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) approval for the cobas® HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, a collection medium commonly used for Pap tests. The Roche test is now the only Human Papillomavirus (HPV) test approved for use as a primary (first-line) screening test with both SurePath and ThinPrep PreservCyt Solution, the two types of liquid media used to collect samples for the vast majority of Pap or HPV tests in the U.S. With this FDA decision, the cobas HPV Test is now approved for all of the cervical cancer screening indications that are supported by professional society guidelines—primary screening in women 25 and older, reflex (follow-up) testing of unclear Pap test results in women 21 and older and co-testing with a Pap test in women 30 and older—with both of the primary collection media types.
AbbVie's (ABBV) Q2 earnings top estimates with revenues marginally beating the same. Revenues increase on strong sales growth of Humira, Imbruvica and Mavyret.
Roche's (RHHBY) performance in the first half is buoyed by solid strength in new drugs like Ocrevus. The increase in guidance is impressive as well.
AG on Thursday raised its annual guidance for the second straight time this year as it posted results that beat expectations, but confirmed it would restructure its pharmaceuticals division to consist of two organizations. Restructuring plans at the Swiss pharmaceutical giant could affect dozens of employees world-wide as the company seeks to decentralize its operations in a bid to become more competitive, according to a person familiar with the matter. Roche told around 350 managers about the restructuring in its pharmaceuticals division at the beginning of the month, when it laid out plans for regional offices to shut down in an effort to decentralize, removing regional intermediaries, the person said.
Winnie the Pooh is returning to theaters today in ‘Christopher Robin.’ The highly-anticipated movie, however, might fall short of stealing the number one spot from ‘Mission Impossible: Fallout’ at the box office. Yahoo Finance’s Alexis Christoforous, Dan Howley and Julia La Roche discuss.
Walmart is testing grocery-picking robots at a store in New Hampshire. Yahoo Finance’s Alexis Christoforous speaks with Julia La Roche and Daniel Howley about what it means.